Experiment Outlining The Effects of Anti-Appetite Drug
In recent years, a variety of new methods of appetite control have been marketed to consumers, both in America and around the globe. There are a variety of different methods, as well, ranging from pure diet and exercise to extreme options like the roux-en-y gastric bypass, meant to prevent absorption of many nutrients by our system. Recently, however, a breakthrough drug has been discovered that mimics the effects of gastric bypass in the sense that it practically reduces the size of the stomach without the risks and dangers of surgery and the potential for complications from the gastric bypass procedure. This new drug has been found effective in small research studies to work with the body to reduce the amount of food eaten, rather than by limiting the absorption of food in the digestive tract. With the successes that have been seen in preliminary research, a grant was given to commission this study, which will examine on a far larger scale whether the relationships that were found in preliminary research will stand up when the drug is given to a much larger sample group. Methodology
The methodology for this experiment is relatively simple, although for the sake of thoroughness, does need to explained in order to fully understand the scope of the proposed study. The first thing that needs to be discussed is the selection of our participants. While it is possible to gather information by randomly selecting people to participate in this study, the results need to be as accurate as possible. As such, the conclusions that are to be drawn at the end of the study need to be based on data gathered from people who would likely be real-world users of this drug. As such, the participant group needs to be modified to include only participants who are morbidly obese. For the purposes of this study, the definition of morbid obesity from the National Center for Biotechnology Information (abb. NCBI, a sub-division of the National Institute for Health, abb. NIH) will be used. The NCBI defines morbid obesity as being 100 pounds or more over the target weight for a given age & height, or having a BMI greater than 40kg/m2 (Obesity, n.d.).
With a participant group defined, the next step is to look at the actual methodology for conducting the study. There are two options for how we can conduct this study. The first is to use a fully laboratory-like setting, hospitalizing patients while they participate to ensure that food quantity and quality are the same among all participants. Now, while this is a fundamentally sound idea in theory, it cannot be implemented without compromising the data that would otherwise be collected. The chances are that the participants in our study did not become obese while eating food from a hospital. Therefore, this study must leave the control of deciding where to eat, what to eat and how much to eat directly in the hands of participants. This way, they can maintain their current lifestyle and see if the drug will work for them to decrease their appetite in their natural setting, rather than being held in some sort of proverbial mouse cage with the inability to behave naturally. In order to accurately measure the effects of the drug that is on trial, there must be a form of control group. Even though this study cannot be performed in a purely laboratory setting, there should be as much done as possible to ensure the legitimacy of this experiment. Therefore, this study will equally divide participants into two groups, a control group who will receive a placebo, and a test group who will receive the real drug.
Many people will also agree, as well, that losing weight is not a process that happens overnight. Therefore, this study must be a longitudinal study, tracking the results of participants with a repeated measures design. Participants will be scheduled...